<DOC>
	<DOCNO>NCT00395317</DOCNO>
	<brief_summary>SB-683699 oral medication think reduce number active white blood cell enter brain ; white blood cell part disease process MS . This study look whether different dos SB-683699 effective safe patient relapse remit MS .</brief_summary>
	<brief_title>Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis ( MS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>Inclusion criterion : Written inform consent Males female , age 18 65 , inclusive A diagnosis relapsingremitting MS [ Polman , 2005 ; McDonald , 2001 ] dissemination time space EDSS 0 6.0 inclusive Screening visit Occurrence least two relapse previous 24 month least one relapse document evidence gadoliniumenhancement MRI ( prior screening ) previous 12 month . Subject must relapse within 4 week prior Screening . In addition , subject experience relapse Screen Visit 3 eligible randomize . A minimum five T2 lesion brain MRI Visit 2 determine central MRI analysis reader A female subject eligible enter study : Of nonchildbearing potential , i.e . woman : document evidence tubal ligation , bilateral oophorectomy hysterectomy ; postmenopausal , define least one year without menses absence hormone replacement therapy . In questionable case , menopausal status confirm oestradiol FSH level consistent menopause accord local laboratory range . Oestrogencontaining hormone replacement therapy allow study . Of childbearing potential , negative urine pregnancy test Screening , agree consistent correct use one method contraception list . Subjects use contraceptive method least one month prior Screening continue use contraceptive method throughout study least 3 day last dose investigational product . Progesteroneonly oral contraceptive implant ( insert least one month prior Screening , beyond third successive year follow insertion ) . Oestrogencontaining contraceptive allow study . Intrauterine device ( IUD ) insert qualified clinician . The IUD must publish data show high expected failure rate le 1 % per year . Spermicide conjunction either diaphragm , cervical cap condom . Male partner sterilization ( vasectomy ) prior female subject 's entry study sole partner female subject In France , subject eligible inclusion study either affiliate beneficiary social security category . Subjects receive corticosteroid within 4 week Screening treatment MS . If nonsystemic steroid use chronic inflammatory condition , subject may include discretion investigator discussion GSK medical monitor Use binterferon product , glatiramer acetate azathioprine within 3 month Screening , use Mitoxantrone within 12 month Screening . Subjects receive therapy affect immune system ( intravenous immunoglobulin ( IVIg ) , cyclophosphamide , plasmapheresis , immunosuppressive immunomodulatory treatment ) past may include case case basis discussion GSK medical monitor . None treatment allow study Previous exposure alemtuzumab , natalizumab firategrast administration , bone marrow transplantation whole body irradiation Subjects cardiac pacemaker type metal implant contraindication MRI ( include know allergy gadolinium ) Use 4aminopyridine , rosiglitazone , pioglitazone drug inhibitor substrate ( low therapeutic index ) OATP Screening . Subjects clinically significant renal laboratory value : subject calculate creatinine clearance &lt; 60ml/min ( Cockcroft Gault ) Screening Subjects local urinalysis finding 1 ) proteinuria , define ≥1+ protein , urine dipstick 2 ) renal tubular cell cast 3 ) ≥5 red blood cell / high power field exclude study result still present repeat urinalysis screen period . Presence clinically significant hepatic laboratory value : ALT , AST , GGT &gt; 2.0 time upper limit normal ( ULN ) ; total bilirubin &gt; 1.5 time ULN Screening CD4 count &lt; 500 , CD4 : CD8 &lt; 1.0 ( result still present repeat test screen period ) , JC viremia detect plasma white cell , idiopathic CD4/CD8 lymphopenia secondary lymphopenia Screening Any finding MRI brain Visit 2 MS , except benign finding ( opinion central MRI reading site local site investigator ) require evaluation treatment impact patient 's neurological health ( e.g. , small arachnoid cyst , venous angioma ) Current history cancer , exclude localize nonmelanoma skin cancer Uncontrolled active bacterial , viral , fungal infection Screening . Any previous serious infection discuss GSK medical monitor ( e.g . opportunistic atypical infection ) History tuberculosis ( TB ) positive chest Xray TB Screening ( prior chest Xray acceptable perform within previous 6 month ) Known congenital acquire immunodeficiency Any abnormality 12lead ECG Screening clinically significant opinion investigator Subjects positive hepatitis B surface antigen , hepatitis C antibody , HIV test Screening Women lactate , pregnant ( positive pregnancy test Screening ) , plan become pregnant course study Recent history suspicion current drug abuse ( include analgesic abuse ) alcohol abuse within last 6 month prior Screening Use investigational drug condition MS within 30 day five half‑lives ( whichever longer ) precede Screening . Prior use investigational drug MS discuss GSK medical monitor Any concurrent illness , disability clinically significant abnormality ( include laboratory test ) may affect interpretation clinical efficacy safety data prevent subject safely complete assessment require protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>magnetic resonance imaging</keyword>
	<keyword>multiple sclerosis</keyword>
	<keyword>SB-683699</keyword>
</DOC>